About KOSELUGO® KOSELUGO® is redefining the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) and can achieve durable PN volume reduction with continued treatment.1,2 Please refer to your local KOSELUGO® label for full prescribing information.
advance I am a healthcare professional registered in the EU I am not a
healthcare professional
Please refer to your local KOSELUGO® label for full prescribing information.*
*There are special safety considerations for the use of KOSELUGO®, please refer to the SmPC for full safety information.
Most adverse events can be managed by dose interruption, reduction, or discontinuation. In Phase I of the SPRINT trial (N = 24), 13 patients required dose reduction for toxicity, and 3 patients discontinued treatment due to an adverse event possibly related to treatment. In SPRINT Phase II Stratum 1 (N = 50), 16 patients had ≥ 1 dose reduction and 5 patients discontinued treatment due to an adverse event possibly related to treatment.3
KOSELUGO® is a selective inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK 1/2). KOSELUGO® blocks MEK activity and the rat sarcoma (RAS)- rapidly accelerated fibrosarcoma (RAF)-MEK- extracellular signal-regulated kinase (ERK) pathway. Therefore MEK inhibition can block the proliferation and survival of tumour cells in which the RAS-RAF-MEK-ERK pathway is activated.1,4
CI, confidence interval; ERK, extracellular signal-regulated kinase; GDP, guanosine diphosphate; GTP, guanosine triphosphate; MEK, mitogen-activated protein kinase kinase; NF1, neurofibromatosis type 1; PN, plexiform neurofibroma; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma viral oncogene homologue.
AstraZeneca AB. KOSELUGO® (selumetinib) Summary of Product Characteristics. 2024. Gross AM et al. Selumetinib in children with inoperable plexiform neurofibromas. N Engl J Med. 2020;382(15):1430–1442. Gross AM et al. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas. Neuro Oncol. 2023;25(10):1883–1894. Yap YS et al. The NF1 gene revisited – from bench to bedside. Oncotarget. 2014;5(15):5873–5892.

*Please refer to the below KOSELUGO® labels for full prescribing information:
KSA: AstraZeneca AB. KOSELUGO® (selumetinib) Summary of Product Characteristics. 2024.
GCC: Koselugo™. Prescribing Information.